The studies were presented and sponsored by J&JPRD, which filed for U.S. approval of OROS(R) MPH for the treatment of adult ADHD last year.
The following New Research Posters on OROS(R) MPH will be presented
today at APA:
NR6-019: Cardiovascular Safety Data From a Long-Term, Open-Label Study of
OROS(R) MPH in Adults with ADHD
NR6-017: A Long-Term Safety Study of OROS(R) Methlyphenidate in Adults
NR6-034: Cardiovascular Effects of OROS(R) MPH in a Dose-Titration Study
of Adults with ADHD
NR6-014: Treatment Response with OROS(R) MPH in a Dose-Titration Study of
Adults with ADHD
NR6-010: Clinician-Rated and Patient-Rated Symptom Improvement in a
Double-Blind, Placebo-Controlled, Dose-Titration Study of OROS(R) MPH in
Adults with ADHD
NR6-005: Efficacy of OROS(R) MPH in a Double-Blind, Placebo-Controlled,
Dose-Titration Study of Adults with ADHD: Secondary Endpoints
*Dr. Adler has been a consultant, served on advisory boards and received research grants from J&JPRD and McNeil Pediatrics(TM), Division of Ortho- McNeil-Janssen Pharmaceuticals, Inc.
Attention Deficit Hyperactivity Disorder (ADHD) is a common and treatable neuropsychiatric condition, which includes inattention, hyperactivity and impulsivity. According to the National Institutes of Mental Health (NIMH), ADHD is one of the most common mental disorders in childhood. It affects an estimated four million children and adolescents in the United States.
Important Safety Information
OROS(R) MPH should not be taken by patients with: significant anxiety,
tension or agitation; allergies to methylphenidate or other ingredients in
OROS(R) MPH; glaucoma; Tourette's syndrome, tics or family history of
|SOURCE McNeil Pediatrics(TM), Division of Ortho-McNeil-Janssen|
Copyright©2008 PR Newswire.
All rights reserved